Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining
Open Access
- 1 January 2006
- journal article
- research article
- Published by Elsevier in Laboratory Investigation
- Vol. 19 (12) , 1631-1637
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Usefulness of HBME‐1, cytokeratin 19 and galectin‐3 immunostaining in the diagnosis of thyroid malignancyHistopathology, 2005
- Galectin‐3 does not reliably distinguish benign from malignant thyroid neoplasmsHistopathology, 2005
- Galectin‐3 is not useful in thyroid FNACytopathology, 2005
- Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumorsLaboratory Investigation, 2005
- Galectin‐3 does not reliably distinguish benign from malignant thyroid neoplasmsHistopathology, 2004
- Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)‐like nuclear alterations express molecular markers of PTCHistopathology, 2004
- CITED1 Protein Expression Suggests Papillary Thyroid Carcinoma in High Throughput Tissue Microarray-Based StudyThyroid®, 2004
- Immunohistochemical Diagnosis of Papillary Thyroid CarcinomaLaboratory Investigation, 2001
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- Pattern of expression of intermediate cytokeratin filaments in the thyroid gland: an immunohistochemical study of simple and stratified epithelial-type cytokeratinsVirchows Archiv, 1997